Ionis Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IONS research report →
Companywww.ionispharma.com
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy.
- CEO
- Brett Monia
- IPO
- 1991
- Employees
- 1,069
- HQ
- Carlsbad, CA, US
Price Chart
Valuation
- Market Cap
- $12.38B
- P/E
- -37.81
- P/S
- 11.70
- P/B
- 25.13
- EV/EBITDA
- 3.14
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 98.35%
- Op Margin
- -33.35%
- Net Margin
- -30.87%
- ROE
- -58.57%
- ROIC
- -11.14%
Growth & Income
- Revenue
- $944.00M · 33.87%
- Net Income
- $-381,000,000 · 16.06%
- EPS
- $-2.38 · 21.71%
- Op Income
- $-382,000,000
- FCF YoY
- 41.41%
Performance & Tape
- 52W High
- $86.74
- 52W Low
- $32.00
- 50D MA
- $74.18
- 200D MA
- $71.69
- Beta
- 0.38
- Avg Volume
- 2.07M
Get TickerSpark's AI analysis on IONS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Start Free Trial →Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 14, 26 | Monia Brett P | other | 3,220 |
| May 13, 26 | Monia Brett P | other | 1,316 |
| May 14, 26 | Monia Brett P | sell | 3,220 |
| May 13, 26 | Monia Brett P | sell | 1,316 |
| May 13, 26 | Monia Brett P | other | 1,316 |
| May 14, 26 | Monia Brett P | other | 3,220 |
| May 4, 26 | LOSCALZO JOSEPH | other | 16,000 |
| May 4, 26 | LOSCALZO JOSEPH | other | 12,000 |
| May 4, 26 | LOSCALZO JOSEPH | other | 16,000 |
| May 4, 26 | LOSCALZO JOSEPH | other | 10,321 |
Our IONS Coverage
We haven't published any research on IONS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IONS Report →